Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN A BERNSTEIN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1093713638
CMS profile
48714
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$100,887.62

147 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN A BERNSTEIN

NPI 1093713638 · CMS profile ID 48714

Allopathic & Osteopathic Physicians / Allergy & Immunology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093713638?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN A BERNSTEIN, NPI 1093713638, CMS profile ID 48714. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093713638?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JONATHAN A BERNSTEIN, NPI 1093713638, CMS profile ID 48714. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093713638?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JONATHAN A BERNSTEIN, NPI 1093713638, CMS profile ID 48714, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1093713638?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

147 matching records · $100,887.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 147 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 147.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.0708/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191002269 CMS
CSL Behring $1,320.0007/31/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232341944 CMS
Azurity Pharmaceuticals, Inc. $18.9607/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242668219 CMS
CSL Behring $672.6007/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232341922 CMS
CSL Behring $6.7607/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232341924 CMS
Blueprint Medicines Corporation $25.4207/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235820715 CMS
Novartis Pharmaceuticals Corporation $133.0407/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200005824 CMS
GlaxoSmithKline, LLC. $13.6507/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190609569 CMS
Grifols USA, LLC $22.9807/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249589169 CMS
CSL Behring $990.0007/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232341970 CMS
CSL Behring $10.3807/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232341878 CMS
GENZYME CORPORATION $22.7306/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233237929 CMS
Ionis Pharmaceuticals, Inc. $14.3306/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246780310 CMS
Pharming Healthcare, Inc. $173.0806/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200796053 CMS
Pharming Healthcare, Inc. $5,625.0006/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200796055 CMS
Pharming Healthcare, Inc. $530.0006/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796057 CMS
CSL Behring $18.6206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232341872 CMS
BioCryst Pharmaceuticals, Inc. $10.6506/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222009968 CMS
KYOWA KIRIN, INC. $70.4906/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222074783 CMS
Takeda Pharmaceuticals U.S.A., Inc. $836.5506/12/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223786589 CMS
Novartis Pharmaceuticals Corporation $11.6806/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200005832 CMS
GENZYME CORPORATION $18.4006/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233237925 CMS
HOSPIRA, INC. $13.5006/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228887062 CMS
CSL Behring $8.4506/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232341876 CMS
CSL Behring $1,576.7305/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232341918 CMS
CSL Behring $382.4805/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232341920 CMS
Pharming Healthcare, Inc. $167.6805/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200796033 CMS
Pharming Healthcare, Inc. $5,625.0005/29/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200796035 CMS
Pharming Healthcare, Inc. $254.8005/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796037 CMS
Pharming Healthcare, Inc. $30.0005/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796039 CMS
Pharming Healthcare, Inc. $296.3705/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796041 CMS
Pharming Healthcare, Inc. $108.0005/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796043 CMS
Pharming Healthcare, Inc. $36.6005/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796045 CMS
Pharming Healthcare, Inc. $20.9305/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796047 CMS
Pharming Healthcare, Inc. $108.0005/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796049 CMS
Pharming Healthcare, Inc. $46.0005/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200796051 CMS
PFIZER INC. $16.4005/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231334177 CMS
Takeda Pharmaceuticals U.S.A., Inc. $836.5505/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223786587 CMS
Phathom Pharmaceuticals, Inc. $12.4405/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219293720 CMS
BioCryst US Sales Co., LLC $26.8105/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222020341 CMS
CSL Behring $2,031.7805/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232341914 CMS
CSL Behring $1,051.1505/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1232341916 CMS
GlaxoSmithKline, LLC. $20.1305/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190916145 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,653.3305/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1223794067 CMS
Blueprint Medicines Corporation $26.1305/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235820640 CMS
Novartis Pharmaceuticals Corporation $9.3005/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200005822 CMS
Pharming Healthcare, Inc. $2,250.0005/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200796031 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.7205/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223863629 CMS
Novartis Pharmaceuticals Corporation $106.4805/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200037546 CMS
Novartis Pharmaceuticals Corporation $10,000.0005/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200037548 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $214,430.29 249
PY2020 $137,330.18 123
PY2021 $157,123.31 171
PY2022 $72,759.52 98
PY2023 $64,236.66 114
PY2024 $63,703.26 115
PY2025 $100,887.62 147

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $20,089.18 6
PY2025 Principal investigator $405,054.18 96
PY2024 Recipient $24,796.06 12
PY2024 Principal investigator $324,932.20 75
PY2023 Recipient $16,377.63 10
PY2023 Principal investigator $201,175.21 57
PY2022 Recipient $16,846.00 3
PY2022 Principal investigator $505,571.69 128
PY2021 Recipient $8,808.00 8
PY2021 Principal investigator $822,738.53 220
PY2020 Principal investigator $475,283.95 113
PY2019 Recipient $983.08 2
PY2019 Principal investigator $988,525.04 109

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

102 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ionis Pharmaceuticals, Inc. $11.31 12/30/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246791986
Principal investigator 1 Ionis Pharmaceuticals, Inc. $47.87 12/30/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246791990
Principal investigator 1 CSL Behring $350.00 12/22/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673328
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,663.64 12/22/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246791691
Principal investigator 1 CSL Behring $1,592.00 12/15/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673326
Recipient Novartis Pharmaceuticals Corporation $2,710.63 12/12/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291527
Principal investigator 1 Ionis Pharmaceuticals, Inc. $47.98 12/10/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246791328
Principal investigator 1 Ionis Pharmaceuticals, Inc. $6,889.68 12/10/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246791332
Principal investigator 1 Ionis Pharmaceuticals, Inc. $8,011.60 12/10/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246791357
Principal investigator 1 CSL Behring $350.00 12/03/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673324
Principal investigator 1 GlaxoSmithKline, LLC. $700.53 11/24/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192147684
Principal investigator 1 GlaxoSmithKline, LLC. $1,030.00 11/24/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192147689
Principal investigator 1 GlaxoSmithKline, LLC. $32,784.84 11/21/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192099266
Principal investigator 1 CSL Behring $350.00 11/20/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673320
Principal investigator 1 CSL Behring $2,184.00 11/20/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673322
Principal investigator 1 GlaxoSmithKline, LLC. $927.00 11/20/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192147669
Principal investigator 1 GlaxoSmithKline, LLC. $525.00 11/20/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192147674
Principal investigator 1 GlaxoSmithKline, LLC. $165.00 11/19/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192099276
Principal investigator 1 GlaxoSmithKline, LLC. $2,856.00 11/19/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192147665
Principal investigator 1 CSL Behring $1,000.00 11/13/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673254
Recipient GENZYME CORPORATION $500.00 11/07/2025 Covered Recipient Physician Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1226089163
Principal investigator 1 GlaxoSmithKline, LLC. $47.78 11/05/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154625
Principal investigator 1 GlaxoSmithKline, LLC. $2,496.70 10/28/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154642
Principal investigator 1 CSL Behring $46.35 10/23/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673250
Principal investigator 1 GlaxoSmithKline, LLC. $9,303.03 10/23/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192099282
Principal investigator 1 CSL Behring $4,002.00 10/22/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673318
Principal investigator 1 Ionis Pharmaceuticals, Inc. $46.35 10/17/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246789474
Principal investigator 1 CSL Behring $3,996.00 10/14/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673248
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,053.98 10/14/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246789286
Principal investigator 1 GlaxoSmithKline, LLC. $47.41 10/08/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154652
Principal investigator 1 Novartis Pharmaceuticals Corporation $50,132.57 10/01/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190306475
Principal investigator 1 SANOFI US SERVICES INC. $5,467.50 10/01/2025 Non-covered Recipient Entity
University Of Cincinnati Physicians
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226098849
Principal investigator 1 SANOFI US SERVICES INC. $2,700.00 10/01/2025 Non-covered Recipient Entity
University Of Cincinnati Physicians
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226098854
Principal investigator 1 CSL Behring $350.00 09/30/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673316
Principal investigator 1 GlaxoSmithKline, LLC. $18.12 09/25/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192147693
Principal investigator 1 GlaxoSmithKline, LLC. $17,466.39 09/24/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192099288
Principal investigator 1 CSL Behring $44.91 09/18/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673240
Principal investigator 1 CSL Behring $3,604.00 09/15/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673314
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,057.86 09/15/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246787378
Principal investigator 1 CSL Behring $300.00 09/11/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673238
Principal investigator 1 SANOFI US SERVICES INC. $2,222.10 09/10/2025 Non-covered Recipient Entity
University Of Cincinnati Physicians
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226098825
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 09/03/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192099261
Principal investigator 1 GlaxoSmithKline, LLC. $6,924.67 09/03/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192147661
Principal investigator 1 GlaxoSmithKline, LLC. $1,084.00 09/03/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192147679
Principal investigator 1 GlaxoSmithKline, LLC. $42.39 08/26/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154638
Principal investigator 1 Ionis Pharmaceuticals, Inc. $42.37 08/25/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246786844
Principal investigator 1 GlaxoSmithKline, LLC. $19,078.29 08/22/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154647
Principal investigator 1 CSL Behring $42.37 08/19/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673234
Principal investigator 1 CSL Behring $1,802.00 08/18/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673312
Principal investigator 1 CSL Behring $228.32 08/14/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673054
Principal investigator 1 CSL Behring $44.92 08/13/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673228
Principal investigator 1 CSL Behring $50.00 08/13/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673230
Principal investigator 1 CSL Behring $300.00 08/13/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673232
Principal investigator 1 CSL Behring $8,694.00 08/12/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673226
Principal investigator 1 Ionis Pharmaceuticals, Inc. $7,512.56 08/07/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246786349
Principal investigator 1 GlaxoSmithKline, LLC. $2,793.16 08/01/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192099270
Principal investigator 1 GlaxoSmithKline, LLC. $986.00 08/01/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154629
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 08/01/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154655
Principal investigator 1 CSL Behring $50.00 07/29/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673308
Principal investigator 1 CSL Behring $350.00 07/29/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673310
Principal investigator 1 SANOFI US SERVICES INC. $3,408.75 07/25/2025 Non-covered Recipient Entity
University Of Cincinnati Physicians
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis No dispute reported 06/30/2026 1226098836
Principal investigator 1 CSL Behring $40.28 07/24/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673220
Principal investigator 1 CSL Behring $300.00 07/24/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673222
Principal investigator 1 GlaxoSmithKline, LLC. $32,850.18 07/18/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154634
Principal investigator 1 CSL Behring $1,870.00 07/14/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673306
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,384.64 07/14/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246785251
Principal investigator 1 CSL Behring $31.35 06/25/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673210
Principal investigator 1 CSL Behring $300.00 06/25/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673212
Principal investigator 1 GlaxoSmithKline, LLC. $13,242.00 06/25/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192158541
Principal investigator 1 CSL Behring $150.00 06/24/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673206
Principal investigator 1 CSL Behring $10,002.16 06/24/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673208
Principal investigator 1 CSL Behring $350.00 06/20/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673304
Principal investigator 1 CSL Behring $150.00 06/19/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673204
Principal investigator 1 CSL Behring $1,870.00 06/09/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673302
Principal investigator 1 CSL Behring $225.00 06/04/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673298
Principal investigator 1 CSL Behring $350.00 06/04/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673300
Principal investigator 1 CSL Behring $350.00 06/02/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673296
Principal investigator 1 CSL Behring $5,714.00 05/30/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673294
Recipient F. Hoffmann-La Roche AG $1,863.75 05/29/2025 Covered Recipient Physician A Phase III Trial of Xolair in CIU No dispute reported 06/30/2026 1211536797
Principal investigator 1 CSL Behring $203.50 05/28/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673170
Principal investigator 1 CSL Behring $12,040.00 05/28/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673202
Principal investigator 1 CSL Behring $2,182.00 05/14/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673292
Recipient F. Hoffmann-La Roche AG $3,666.67 05/09/2025 Covered Recipient Physician Omalizumab for People with Chronic Spontaneous Urticaria: Plain Language Summary of a Review No dispute reported 06/30/2026 1211536793
Principal investigator 1 CSL Behring $350.00 04/28/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673290
Principal investigator 1 CSL Behring $375.00 04/21/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673288
Principal investigator 1 CSL Behring $1,904.00 04/11/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673286
Recipient F. Hoffmann-La Roche AG $3,666.67 04/11/2025 Covered Recipient Physician Associations between comorbidities, disease activity and response to ocrelizumab in the CHIMES trial No dispute reported 06/30/2026 1211536790
Principal investigator 1 CSL Behring $2,503.00 03/26/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673158
Principal investigator 1 CSL Behring $1,904.00 03/14/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673276
Principal investigator 1 CSL Behring $4,364.00 03/12/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673274
Principal investigator 1 CSL Behring $50.00 03/05/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673268
Principal investigator 1 CSL Behring $300.00 03/05/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673270
Principal investigator 1 CSL Behring $1,130.00 03/05/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673272
Recipient Novartis Pharmaceuticals Corporation $7,681.46 02/27/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292096
Principal investigator 1 CSL Behring $1,904.00 02/19/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673266
Principal investigator 1 Amgen Inc. $6,293.02 02/18/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1246639605
Principal investigator 1 CSL Behring $226.72 02/05/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673050
Principal investigator 1 Amgen Inc. $6,672.01 01/30/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246639603
Principal investigator 1 CSL Behring $364.28 01/27/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673186
Principal investigator 1 CSL Behring $350.00 01/22/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252673264
Principal investigator 1 Amgen Inc. $59,311.74 01/21/2025 Non-covered Recipient Entity
BERNSTEIN CLINICAL RESEARCH CENTER LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639599
Principal investigator 1 CSL Behring $1,904.00 01/17/2025 Non-covered Recipient Entity
Bernstein Clinical Research Center
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673262